Synthesis of salicylate dendritic prodrugs

Tang, Shengzhuang; June, Stephen M.; Howell, Bob A.; Chai, Minghui

doi:10.1016/j.tetlet.2006.08.110

Cited by 31 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SA has been incorporated into poly(anhydride-esters), 16,17 dendrimers, 18 biopolymers, 19 micelles, 20 polyurethanes 21 etc. for use as an anti-inflammatory, anti-oxidative, antibacterial and/or antibiofilm formation agent.…”

Section: Introductionmentioning

confidence: 99%

Controlled Release of Salicylic Acid from Biodegradable Cross-Linked Polyesters

2015

View full text Add to dashboard Cite

The purpose of this work was to develop a family of cross-linked poly(xylitol adipate salicylate)s with a wide range of tunable release properties for delivering pharmacologically active salicylic acid. The synthesis parameters and release conditions were varied to modulate polyester properties and to understand the mechanism of release. Varying release rates were obtained upon longer curing (35% in the noncured polymer to 10% in the cured polymer in 7 days). Differential salicylic acid loading led to the synthesis of polymers with variable cross-linking and the release could be tuned (100% release for the lowest loading to 30% in the highest loading). Controlled release was monitored by changing various factors, and the release profiles were dependent on the stoichiometric composition, pH, curing time, and presence of enzyme. The polymer released a combination of salicylic acid and disalicylic acid, and the released products were found to be nontoxic. Minimal hemolysis and platelet activation indicated good blood compatibility. These polymers qualify as "bioactive" and "resorbable" and can, therefore, find applications as immunomodulatory resorbable biomaterials with tunable release properties.

show abstract

Section: Introductionmentioning

confidence: 99%

Controlled Release of Salicylic Acid from Biodegradable Cross-Linked Polyesters

2015

View full text Add to dashboard Cite

show abstract

“…The T g for all of dendrimers, obtained with modulated differential scanning calorimetry (MDSC), ranged from 38–47 °C and from −20 to −13 °C for protected and deprotected dendrimers, respectively. With the use of this same strategy, GLSA–adipic acid G n -dendrimers possessing alternating or block succinate/adipate layers 229 and glycerol– succinic acid–salicylic acid (GLSASAL) G n -dendrimers (Figure 26) 230 can be synthesized.…”

Section: Glycerol Synthonsmentioning

confidence: 99%

Synthetic Biomaterials from Metabolically Derived Synthons

et al. 2016

View full text Add to dashboard Cite

The utility of metabolic synthons as the building blocks for new biomaterials is based on the early application and success of hydroxy acid based polyesters as degradable sutures and controlled drug delivery matrices. The sheer number of potential monomers derived from the metabolome (e.g., lactic acid, dihydroxyacetone, glycerol, fumarate) gives rise to almost limitless biomaterial structural possibilities, functionality, and performance characteristics, as well as opportunities for the synthesis of new polymers. This review describes recent advances in new chemistries, as well as the inventive use of traditional chemistries, toward the design and synthesis of new polymers. Specific polymeric biomaterials can be prepared for use in varied medical applications (e.g., drug delivery, tissue engineering, wound repair, etc.) through judicious selection of the monomer and backbone linkage.

show abstract

“…28 In a different approach, polyester dendrimers based on salicylic acid, glycerol, and succinic acid have also been described up to generation 3 containing sixty salicylate moieties, but no data on hydrolysis has been disclosed. 29 The cellular release of the AI can be controlled with other parameters apart from pH modifi cation. For instance, N -acetyl -cysteine (NAC) is an antioxidant and antiinfl ammatory drug which suffers from high plasma binding upon intravenous administration and requires the use of high doses to reach the target microglia cells for the treatment of neuroinfl ammation.…”

Section: Improving Bioavailability With Dendrimersmentioning

confidence: 99%